First Trust Nasdaq Pharmaceuticals ETF
FTXH
13 hedge funds and large institutions have $10.6M invested in First Trust Nasdaq Pharmaceuticals ETF in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
40% more capital invested
Capital invested by funds: $7.57M → $10.6M (+$3M)
2.56% more ownership
Funds ownership: 59.76% → 62.32% (+2.6%)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
+$2.58M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.21M |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$111K |
| 4 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$60.7K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
+$9.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$748K |
| 2 |
LPL Financial
San Diego,
California
|
-$348K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$214K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$20K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$15K |
FTXH Hedge Fund Activity: Q3 2020 in Review
13 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2020, worth a combined $10.6M — up 40% from $7.57M a quarter earlier.
Fund positioning in FTXH was balanced in Q3 2020: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was J. Arnold Wealth Management, adding an estimated $2.58M. The largest seller was Citadel Advisors, exiting entirely with an estimated $748K sold.
- 13 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $10.6M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2020, up 40% quarter-over-quarter.
- 3 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2020 and 3 closed out, a net change of 0 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2020 was J. Arnold Wealth Management, an estimated $2.58M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2020 was Citadel Advisors, an estimated $748K sold.
Based on aggregated 13F filings for Q3 2020.